Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (171-180 of 347) with videos related to

Pageof 35
Sort By:
Frontiers in Oncology|May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myelomaLukas John, Kaya Miah, Axel Benner, et al.
International Journal of Cancer|September 26, 2006
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patientsMuhammad U Rashid, Anbreen Zaidi, Diana Torres, et al.
Brain Pathology (Zurich, Switzerland)|July 6, 2007
DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human GliomasAnnegret Kunitz, Marietta Wolter, Jörg van den Boom, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Anti-Cancer Drugs|October 1, 2004
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphomaJana Schlenzka, Thomas M Moehler, Sergey M Kipriyanov, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Cell Reports|June 14, 2018
Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal CarcinogenesisFelix Bormann, Manuel Rodríguez-Paredes, Felix Lasitschka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculationJens Hillengass, Christian Zechmann, Tobias Bäuerle, et al.
Pageof 35

Showing results (171-180 of 347) with videos related to

Sort By:
Pageof 35
Frontiers in Oncology|May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myelomaLukas John, Kaya Miah, Axel Benner, et al.
International Journal of Cancer|September 26, 2006
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patientsMuhammad U Rashid, Anbreen Zaidi, Diana Torres, et al.
Brain Pathology (Zurich, Switzerland)|July 6, 2007
DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human GliomasAnnegret Kunitz, Marietta Wolter, Jörg van den Boom, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Anti-Cancer Drugs|October 1, 2004
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphomaJana Schlenzka, Thomas M Moehler, Sergey M Kipriyanov, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Cell Reports|June 14, 2018
Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal CarcinogenesisFelix Bormann, Manuel Rodríguez-Paredes, Felix Lasitschka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculationJens Hillengass, Christian Zechmann, Tobias Bäuerle, et al.
Pageof 35